ArticleArchives of medical science : AMS2021

Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience.

Serhat Özçelik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.